View the full Corporate Spotlight arrow Created with Sketch.
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
This exclusive 48-hour opportunity is available only to DealRoom members.
Sign up now to access the deal - and get early access to future offerings.
